Myrosor (Ezetimibe, Rosuvastatin)

Myrosor is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.

• Hypercholesterolemia: reduces elevated LDL‑C and total cholesterol levels.
• Mixed dyslipidemia: improves the overall lipid profile by lowering LDL‑C and triglycerides while raising HDL‑C.
• Primary prevention of cardiovascular events: helps lower risk in patients with high cholesterol who have additional risk factors.

• Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Rosuvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis. The combined effect decreases circulating LDL‑C and total cholesterol, while modestly increasing HDL‑C.

Adverse reactions may occur with Myrosor and should be monitored.

Common Side Effects

• Headache: mild to moderate intensity.
• Myalgia: muscle aches without weakness.
• Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea.
• Elevated liver enzymes: transient increases in ALT/AST.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Acute hepatitis: marked elevation of liver enzymes with jaundice.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Renal impairment: worsening kidney function in susceptible patients.
• Myopathy with statin‑related muscle toxicity.

Before prescribing Myrosor, clinicians should consider several safety aspects.

• Liver function monitoring: assess baseline ALT/AST and repeat periodically.
• Renal function assessment: evaluate creatinine clearance in patients with kidney disease.
• Drug interactions: review concomitant medications that affect statin metabolism.
• Pregnancy and lactation: avoid use due to unknown safety profile.
• Patient education: advise reporting unexplained muscle pain or weakness.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Myrosor may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase rosuvastatin exposure.
• Cyclosporine: markedly raises rosuvastatin levels, raising risk of myopathy.
• Gemfibrozil: enhances statin‑related muscle toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.
• Warfarin: potential alteration of INR, requiring monitoring.
• Niacin: may increase risk of liver enzyme elevations.